Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Fulgent Genetics, Inc. (FLGT) Tops Q4 EPS by $2.15, Revenues Rise 3400%; Raises Outlook
March 4, 2021 4:15 PM ESTFulgent Genetics, Inc. (NASDAQ: FLGT) reported Q4 EPS of $6.20, $2.15 better than the analyst estimate of $4.05. Revenue for the quarter came in at $295 million versus the consensus estimate of $199.44 million.
GUIDANCE:
Fulgent Genetics, Inc. sees FY2021 EPS of $12.50, versus the consensus of $11.55. Fulgent Genetics, Inc. sees FY2021 revenue of $800 million, versus the consensus of $600.24 million.
Ming Hsieh, Chairman and Chief Executive Officer, said, Our record fourth quarter results capped off a transformational year for Fulgent Genetics. While we did not envision 2020 to unfold in... More
